CG Oncology, Inc. Earnings Per Share (Diluted)
CG Oncology, Inc. (CGON) reported Earnings Per Share (Diluted) of -$0.90 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- CG Oncology, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.90.
- CG Oncology, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.71.
- CG Oncology, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.52.
- CG Oncology, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.57.
- CG Oncology, Inc. earnings per share, diluted for fiscal 2025 was -$2.08.
- CG Oncology, Inc. earnings per share, diluted for fiscal 2024 was -$1.41.
- CG Oncology, Inc. earnings per share, diluted for fiscal 2023 was -$15.65.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.90 10-Q · filed 2026-08-06 | -$1.61 10-Q · filed 2026-08-06 | -$2.14 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.72 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.71 10-Q · filed 2026-05-08 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.35 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.09 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.63 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.08 10-K · filed 2026-02-27 |
| 2025-09-30 | -$0.57 10-Q · filed 2025-11-14 | -$1.11 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.57 10-Q · filed 2025-11-14 | -$2.03 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.54 10-Q · filed 2026-08-06 | -$1.00 10-Q · filed 2026-08-06 | -$1.46 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.78 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.45 10-Q · filed 2026-05-08 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.51 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | -$0.46 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$1.41 10-K · filed 2026-02-27 |
| 2024-09-30 | -$0.30 10-Q · filed 2025-11-14 | -$0.59 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$0.93 10-Q · filed 2025-11-14 | -$1.57 derived: net income ÷ weighted average shares · filed 2026-02-27 |
| 2024-06-30 | -$0.28 10-Q · filed 2025-08-08 | -$0.63 10-Q · filed 2025-08-08 | -$1.32 derived: net income ÷ weighted average shares · filed 2026-02-27 | -$2.08 derived: net income ÷ weighted average shares · filed 2026-02-27 |
| 2024-03-31 | -$0.36 10-Q · filed 2025-05-13 | -$1.28 derived: net income ÷ weighted average shares · filed 2026-02-27 | -$2.40 derived: net income ÷ weighted average shares · filed 2026-02-27 | -$3.76 derived: net income ÷ weighted average shares · filed 2026-02-27 |
| 2023-12-31 | -$3.21 derived: net income ÷ weighted average shares · filed 2026-02-27 | -$5.93 derived: net income ÷ weighted average shares · filed 2026-02-27 | -$8.90 derived: net income ÷ weighted average shares · filed 2026-02-27 | -$15.65 10-K · filed 2026-02-27 |
| 2023-09-30 | -$4.00 10-Q · filed 2024-11-12 | -$5.63 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$11.18 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$3.93 10-Q · filed 2024-08-08 | -$7.15 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$3.22 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |